Long-term safety and efficacy of subcutaneous tanezumab in subjects with osteoarthritis of the hip or knee
Chronic Pain · Osteoarthritis, Hip · Osteoarthritis, Knee
Enrolment: 3021 · Results not recorded
Loading the evidence…
Biologic · Class-level entry: no single ChEMBL small molecule applies. Human anti-NGF antibodies are well developed clinically (tanezumab/PF-04383119, fasinumab/REGN475, MT-5547), all in osteoarthritis and low back pain, none in a trauma indication. NCT06348134 (anti-HER2 breast cancer) was returned by the query and REJECTED as an irrelevant growth-factor keyword match.
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Chronic Pain · Osteoarthritis, Hip · Osteoarthritis, Knee
Enrolment: 3021 · Results not recorded
Arthritis · Osteoarthritis · Osteoarthritis, Hip
Enrolment: 627 · Results not recorded
Osteoarthritis
Enrolment: 220 · Results not recorded
Osteoarthritis, Knee / Osteoarthritis, Hip
Enrolment: 626 · Results not recorded
Osteoarthritis, Knee · Osteoarthritis, Hip
Enrolment: 421 · Results not recorded
Osteoarthritis, Knee
Enrolment: 83 · Results not recorded
Low Back Pain
Enrolment: 849 · Results not recorded
Osteoarthritis, Knee · Osteoarthritis, Hip
Enrolment: 679 · Results not recorded
Osteoarthritis Pain · Chronic Low Back Pain · Pain Due to Interstitial Cystitis
Enrolment: 28 · Results not recorded
1 studies reported at therapy level; 1 evidence entries itemised.
Model: Drop-mass contusion injury of the right gastrocnemius muscle, with Fluoro-Gold retrograde tracing of sensory nerves
Anti-NGF antibody reduced muscle necrosis at 1 and 3 days, promoted granulation tissue replacement and muscle fibre regeneration by 7 days, and lowered the proportion of CGRP positive Fluoro-Gold labelled neurons (38.2% versus 49.6% in controls, P<0.05).
Extraction: extract · Subtype source: llm · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.